Phoenix Holdings Ltd. Oramed Pharmaceuticals Inc. Transaction History

Phoenix Holdings Ltd.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$6.21 - $12.03 $19,201 - $37,196	-3,092 Reduced 22.68%	10,542 $126,000
Q3 2022 Nov 10, 2022	SELL	$4.6 - $9.91 $171,653 - $369,801	-37,316 Reduced 73.24%	13,634 $89,000
Q2 2022 Aug 15, 2022	BUY	$3.72 - $9.0 $84,797 - $205,155	22,795 Added 80.96%	50,950 $231,000
Q1 2022 May 10, 2022	SELL	$8.19 - $13.89 $25,986 - $44,072	-3,173 Reduced 10.13%	28,155 $244,000
Q4 2021 Feb 07, 2022	BUY	$12.98 - $29.75 $35,331 - $80,979	2,722 Added 9.52%	31,328 $439,000

Q3 2021 Oct 27, 2021	BUY	$12.13 - $23.82 $11,972 - $23,510	987 Added 3.57%	28,606 $633,000
Q2 2021 Aug 10, 2021	BUY	$8.34 - $14.59 $230,342 - $402,961	27,619 New	27,619 $370,000
Q4 2020 Feb 11, 2021	SELL	$2.48 - $4.64 $490,452 - $917,620	-197,763 Closed	0 $0
Q3 2020 Nov 10, 2020	BUY	$2.58 - $4.16 $39,997 - $64,492	15,503 Added 8.51%	197,763 $483,000
Q2 2020 Aug 10, 2020	BUY	$2.87 - $4.12 $523,086 - $750,911	182,260 New	182,260 $610,000

5.69M

8.3K

2.7K

Ticker ORMP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,827,100
Market Cap $97.8M
Description
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for th...

Get notified when there are updates to the investment portfolio of Phoenix Holdings Ltd., based on Form 13F filings with the SEC.

Stay updated on Phoenix Holdings Ltd. with notifications on news.